These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 23702033)

  • 1. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
    Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
    Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
    Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
    Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in SGC-7901 cells and inhibits tumor growth in vivo.
    Wang YR; Xu Y; Jiang ZZ; Guerram M; Wang B; Zhu X; Zhang LY
    Molecules; 2015 Jan; 20(1):1661-75. PubMed ID: 25608854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the anti-angiogenesis effects induced by deoxypodophyllotoxin-5-FU conjugate C069 against HUVE cells.
    Xiang R; Guan XW; Hui L; Jin YX; Chen SW
    Bioorg Med Chem Lett; 2017 Feb; 27(4):713-717. PubMed ID: 28129979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
    Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
    Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
    Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
    Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
    Yang GW; Jiang JS; Lu WQ
    Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
    Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.